Klebingat K J, Panzig E, Lorenz G, Steinhauser I, Fiedler R
Z Urol Nephrol. 1987 Mar;80(3):139-47.
The influence on the specific cell-mediated immunity (CMI) of the carcinoma of the prostate gland by the contra-sexual hormone therapy with Cytonal, Estrazyt and Turisteron is controlled. For this purpose the macrophage-electrophoresis-mobility test on the basis of allogenic tumour-associated antigen of the carcinoma of the prostate gland is used. As a result the use of Cytonal at least in the dosage hitherto used is no longer worth being advocated. Turisteron and Estrazyt, respectively, taking into consideration their pharmacokinetics and indication, prove to be immunologically optimal and without hesitation, respectively. Turisteron is the basic therapeutic in the androgen-dependent carcinoma of the prostate gland. Estrazyt should be reserved to primarily and secondarily hormone-refractory tumours. For the application of Estrazyt an additive immune stimulation seems to be worth taking into consideration.
研究了使用西托纳尔、雌二醇和去氢表雄酮进行抗性激素治疗对前列腺癌特异性细胞介导免疫（CMI）的影响。为此，采用基于前列腺癌同种异体肿瘤相关抗原的巨噬细胞电泳迁移率试验。结果表明，至少按照目前使用的剂量，西托纳尔不再值得提倡。考虑到其药代动力学和适应症，去氢表雄酮和雌二醇分别被证明在免疫方面是最佳的。去氢表雄酮是雄激素依赖性前列腺癌的基本治疗药物。雌二醇应保留用于原发性和继发性激素难治性肿瘤。对于雌二醇的应用，似乎值得考虑附加免疫刺激。
